Goodwin advised Ampersand Capital Partners on the transaction
Ampersand Capital Partners closed the firm’s latest fund, Ampersand 2018 (“AMP-18”) Limited Partnership, with $450 million in limited partner commitments. This fund, which is Ampersand’s ninth fund since 1992, was significantly oversubscribed and held a single close three months after launch.
Ampersand Managing General Partner, Herb Hooper, commented, “We greatly appreciate the strong support from both existing and new investors, and their confidence in Ampersand’s differentiated healthcare investment strategy.” Ampersand secured commitments from a diversified group of institutional investors including endowments, foundations, pension plans, insurance companies, multi-manager funds and family offices.
With this new fund, Ampersand plans to continue the firm’s strategy of making growth-oriented investments within targeted sectors of the healthcare industry. Ampersand focuses on both majority and minority investments in companies with $10 to $100 million in revenues and positive EBITDA.
Founded in 1988, Am persand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive strong long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. The firm led by Herbert H. Hooper and Richard A. Charpie, is based in Boston and Amsterdam.
Goodwin advised with a team including James Barrett (Picture) and James Donohue and included partner Daniel Karelitz and associates Adam Aramati, Joseph Baron, David Holland and Todd Pollock.
Involved fees earner: James Barrett – Goodwin Procter; James Donohue – Goodwin Procter; Adam Aramati – Goodwin Procter; Joseph Baron – Goodwin Procter; David Holland – Goodwin Procter; Daniel Karelitz – Goodwin Procter; Todd Pollock – Goodwin Procter;
Law Firms: Goodwin Procter;
Clients: Ampersand Capital Partners;